Dr Blackwood on the Significance of Early Breast Cancer Screenings


M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

M. Michele Blackwood, MD, FACS, chief, Section Breast Surgery, Rutgers Cancer Institute of New Jersey, professor of Surgery, Rutgers Robert Wood Johnson Medical School, medical director, The Center for Breast Health and Disease Management, the Barnabas Health Ambulatory Care Center, discusses the significance of early cancer screenings.

According to Blackwood, routine breast cancer screenings play a pivotal role in early detection and subsequent management of breast malignancies. Mammography, the cornerstone of breast cancer screening, enables the identification of subtle abnormalities in breast tissue, often before clinical symptoms manifest. The utilization of mammographic screening has been associated with a significant reduction in breast cancer mortality rates, primarily attributable to the detection of tumors at earlier, more treatable stages, she says. Additionally, advancements in imaging modalities such as digital mammography and tomosynthesis have enhanced the sensitivity and specificity of breast cancer detection, further augmenting the efficacy of routine screenings.

Blackwood explains that early detection through routine screenings enables the implementation of less invasive therapeutic interventions, potentially mitigating the need for extensive surgical procedures and adjuvant therapies, thereby improving patient outcomes and quality of life.

Blackwood also notes that breast cancer screenings serve as a platform for patient education and engagement in health-care decision-making. Clear communication regarding the importance of regular screenings empowers individuals to proactively participate in their own health management, fostering a collaborative patient-physician relationship.

Breast cancer screenings offer substantial benefits in terms of early detection, accurate diagnosis, and improved treatment outcomes, Blackwood continues. Emphasizing the significance of these screenings within clinical practice is paramount in mitigating the burden of breast cancer morbidity and mortality. Current clinical trial pursuits combined with research and advocacy efforts are warranted to optimize screening strategies and ensure equitable access to this vital aspect of breast cancer care, Blackwood concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD